Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference, page-11

Re my comments on other contributors to this forum. For years I have listened to incessant ravings etc etc about all the previous board. It was a waste of air and time. They appear to have gone quiet.

As you agree, nearly everything was set up by the previous management - even bad "management" can have some good ideas.
Without NEXTSTELLIS MYX wouldnt have the first class portfolio and wouldnt be able to attract other items to themselves due to eventual size.
Paying a price for a novel product can always be criticised. We will see in 2 years if it was a high price. Its novel, there is no competition, it could become a billion dollar income.

People can criticise the money spent on launching the product BUT they never put forward any other method of launching. Remember the products they just bought had a very high 2 year launch cost - and it was (probably) one of the reasons the company didnt survive. MYX didnt buy the company when they first looked at it. They walked away and later just took the products that were left when it fell over. Nobody else took the product - probably because the launch and support costs are so great.

The new management have tried a few things and walked back on some ie direct to consumer, because there is insufficient product being sold.
They have also cancelled 6 sale areas BUT have maintained the rest of the 50 odd areas. This means they are affirming the previous decisions. Current management also said in todays presentation that other suppliers of competitive drugs etc have been withdrawing due to the costs. Does anyone know of any other system of distribution like that being implemented by MYX ie from Dr to Pharmacy to Patient.

This is the magic of having so many good/great products to market in both target areas.

YET THE SHARE PRICE HAS GONE DOWN.... Perhaps people need time to understand.